Tokai Ends Cancer Trial After Phase 3 Shows Meager Results

Tokai Pharmaceuticals is stopping work on a Phase 3 trial for a metastatic cancer candidate after getting negative feedback from a review group.

The company called a halt to the work on candidate drug galeterone after a data monitoring committee concluded that the head-to-head trial is unlikely to meet its primary endpoint of improved radiographic progression-free survival versus the drug enzalutamide.

The company says it will continue to allow patients to receive the drug after consulting with their physicians and study investigators.